[{"_1":2,"_3":-5,"_4":-5},"loaderData",{"_5":6,"_7":8},"actionData","errors","root",{"_95":96},"routes/item",{"_9":10},"item",{"_11":12,"_13":14,"_15":16,"_17":18,"_19":20,"_21":-5,"_22":23,"_24":25,"_26":27,"_28":29,"_30":29,"_31":32,"_33":34,"_35":36,"_37":38,"_39":40,"_41":42,"_43":44,"_45":-5,"_46":47,"_48":-5,"_49":-5,"_50":51,"_52":53,"_54":55,"_56":57,"_58":57,"_59":60,"_61":40,"_62":63},"id","x6qfvw3c9btinz1mhyk1gfajd","revision",2,"title","Novavax 获 Sanofi 1.25 亿美元里程碑付款","originalTitle","8-K - NOVAVAX INC (0001000694) (Filer)","summary","Novavax 因 Sanofi 在欧盟启动新冠流感联合疫苗三期试验获 1.25 亿美元付款。付款来自双方合作开发协议。公司预计 2027 年第一季度收到款项。","reason","source",{"_11":85,"_86":87,"_88":89,"_90":57,"_91":92,"_93":94},"links",{"_82":83,"_63":84},"publishedAt","2026-10-29T20:30:21.000Z","discoveredAt","2026-10-30T01:34:51.674Z","timelineAt","category","ai-products","tags",[81],"stockSymbols",[80],"score",42,"selected",false,"channel","news","story",{"_72":73,"_15":74},"x","readingMode","full","author","language","body",{"_76":-5,"_63":77,"_78":-5,"_79":40},"outline",[],"relatedStories",[75],"indexable",true,"markdownAvailable","group",{"_64":65,"_43":66,"_67":68,"_69":70,"_71":70},"hasTranslation","bodyLanguage","original","factId","f2w4aVFZhBCI",{"_72":73,"_15":74},"reportCount",1,"additionalSourceCount",0,"developmentCount","publicId","e3b01a6a-35f2-4eac-a99d-596149ce135e","Novavax 获 Sanofi 1.25 亿美元付款",{"_72":73,"_15":74},"zh","

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934\n

Date of Report (Date of earliest event reported):\nOctober 29, 2026

NOVAVAX, INC.

(Exact name of registrant as specified\nin charter)

\n\n \n \n \n \n \n\n \n \n \n \n \n

Delaware

0-26770

22-2816046

(State or Other Jurisdiction

of Incorporation)

(Commission File Number)

(I.R.S. Employer

Identification No.)

21 Firstfield Road

Gaithersburg, Maryland 20878

(Address of Principal Executive Offices,\nincluding Zip Code)

(240) 268-2000

(Registrant’s telephone number,\nincluding area code)

(Former name or former address, if changed\nsince last report.)

Check the appropriate box below if the Form 8-K\nfiling is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General\nInstruction A.2. below):

\n\n \n \n\n\n \n \n\n \n \n\n\n \n \n\n \n \n\n\n \n \n\n \n \n

¨	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section\n12(b) of the Act:

\n\n \n \n \n \n \n\n \n \n \n \n \n

Title of each class		Trading \nSymbol(s)		Name of each exchange on which \nregistered
Common Stock, Par Value $0.01 per share		NVAX		The Nasdaq Global Select Market

Indicate by check mark whether the registrant\nis an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2\nof the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging\ngrowth company ¨

If\nan emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying\nwith any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 7.01. Regulation FD Information.

On October 29, 2026, Novavax, Inc. (“Novavax”\nor the “Company”) issued a press release announcing the information discussed under Item 8.01 hereof. A copy of the press\nrelease is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information contained in this Item 7.01 shall\nnot be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”),\nor incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly\nset forth by specific reference in such a filing.

Item 8.01. Other Events.

On October 28, 2026 Sanofi Pasteur Inc. (“Sanofi”)\ndosed the fifth patient in its Phase 3 influenza-COVID-19 combination vaccine trial in the European Union, utilizing the Company’s\nCOVID-19 component. Dosing of the fifth patient has triggered a $125 million milestone payment from Sanofi under the Company’s\nCollaboration and License Agreement with Sanofi. The Company anticipates receipt of payment by the first quarter of 2027.

Cautionary Note Regarding Forward-Looking Statements.

This Current Report on Form 8-K contains forward-looking\nstatements within the meaning of the Private Securities Litigation Reform Act of 1995. We intend such forward-looking statements to be\ncovered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 1933, as amended\n(the “Securities Act”) and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”).\nAny statements in the discussion below and elsewhere in this Current Report about expectations, beliefs, plans, objectives, assumptions,\nor future events or performance of the Company are not historical facts and are forward-looking statements. Such forward-looking statements\ninclude, without limitation, statements regarding expected milestone payments under the Sanofi agreement. Generally, forward-looking\nstatements can be identified through the use of words or phrases such as “believe,” “may,” “could,”\n“will,” “would,” “possible,” “can,” “estimate,” “continue,” “ongoing,”\n“consider,” “anticipate,” “intend,” “seek,” “plan,” “project,”\n“expect,” “should,” “would,” “aim,” or “assume,” the negative of these terms,\nor other comparable terminology, although not all forward-looking statements contain these words.

Forward-looking statements are neither historical\nfacts nor assurances of future performance. Instead, they are based only on Novavax’s current beliefs and expectations about the\nfuture of our business, events and trends, and other future conditions. Forward-looking statements involve estimates, assumptions, risks,\nand uncertainties that could cause actual results or outcomes to differ materially from those expressed or implied in any forward-looking\nstatements, and, therefore, you should not place considerable reliance on any such forward-looking statements. Such risks and uncertainties\ninclude, without limitation, challenges related to Novavax's partnership with Sanofi, and in pursuing additional partnership opportunities;\nchallenges satisfying, alone or together with partners, various safety, efficacy, and product characterization requirements, challenges\nor delays in conducting clinical trials or studies for its product candidates; manufacturing, distribution or export delays or challenges;\nNovavax's substantial dependence on Serum Institute of India Pvt. Ltd. and Serum Life Sciences Limited for co-formulation and filling\nNovavax's COVID-19 vaccine and the impact of any delays or disruptions in their operations; the impact of potential legislative, regulatory,\nor policy changes under the current presidential administration, including any adverse impact funding for vaccine research and development,\nreimbursement for vaccines and their administration, vaccine mandates and recommendations, and public perception of vaccine importance;\nuncertainty with respect to pricing, third-party reimbursement and healthcare reform; the impact of any new or changes in interpretations\nof existing trade measures, including tariffs, embargoes, sanctions, import restrictions, and export licensing requirements; difficulty\nobtaining scarce raw materials and supplies including for its proprietary adjuvant; resource constraints, including human capital and\nmanufacturing capacity; constraints on Novavax's ability to pursue planned regulatory pathways, alone or with partners, in multiple jurisdictions\nsimultaneously, leading to staggering of regulatory filings, and potential regulatory actions; Novavax's ability to timely deliver doses;\nchallenges in obtaining commercial adoption and market acceptance of its COVID-19 vaccine or any COVID-19 variant strain containing formulation,\nor for its CIC vaccine candidates, stand-alone influenza vaccine candidates or other candidates; challenges meeting contractual requirements\nunder agreements with multiple commercial, governmental, and other entities, including requirements to deliver doses that may require\nNovavax to refund portions of upfront and other payments previously received or result in reduced future payments pursuant to such agreements;\nchallenges related to the seasonality of vaccinations against COVID-19; challenges related to the demand for vaccinations against COVID-19\nor influenza; challenges in identifying and successfully pursuing innovation expansion opportunities; Novavax's expectations as to expenses\nand cash needs may prove not to be correct for reasons such as changes in plans or actual events being different than its assumptions;\nand other risks and uncertainties identified in Part I, Item 1A “Risk Factors” of our Annual Report on Form 10-K for the year\nended December 31, 2025, filed with the Securities and Exchange Commission (“SEC”) on February 26, 2026, as updated by the\ninformation in Part II, Item 1A “Risk Factors” in our subsequent Quarterly Reports on Form 10-Q which may be further detailed\nand modified or updated in other documents we file with the SEC from time to time, and are available at www.sec.gov and at www.novavax.com.\nYou are encouraged to read these filings as they are made.

Novavax cannot guarantee future results, events, level of activity,\nperformance, or achievement. Any or all of Novavax’s forward-looking statements in this Current Report on Form 8-K may turn out\nto be inaccurate or materially different from actual results. Further, any forward-looking statement speaks only as of the date when it\nis made, and Novavax undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information,\nfuture events, or otherwise, unless required by law. New factors emerge from time to time, and it is not possible for Novavax to predict\nwhich factors will arise. In addition, Novavax cannot assess the impact of each factor on our business or the extent to which any factor,\nor combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

\n \n \n \n \n \n \n \n \n \n \n \n \n

Exhibit No.		Description
99.1		Press release, Dated October 29, 2026
104		Cover Page Interactive Data File (formatted as Inline XBRL).

SIGNATURES

Pursuant\nto the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the\nundersigned hereunto duly authorized.

\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n

	Novavax, Inc.

Date: October 29, 2026	By:	/s/ Mark J. Casey
	Name:	Mark J. Casey
	Title:	Executive Vice President, Chief Legal Officer and Corporate Secretary

","zhKind","complete","NVAX","其他","aihot","/items/x6qfvw3c9btinz1mhyk1gfajd","https://www.sec.gov/Archives/edgar/data/1000694/000110465926120221/0001104659-26-120221-index.htm","rss-sec-xbrl","name","SEC · EDGAR 财务披露","kind","rss","firstParty","iconUrl","/api/img-proxy?u=https%3A%2F%2Fwww.sec.gov%2Fthemes%2Fcustom%2Fuswds_sec%2Fassets%2Fimg%2Ffavicons%2Fapple-touch-icon.png&mode=avatar&exp=1793923200&sig=9d3ad08db2303b57","iconSrcSet","/api/img-proxy?u=https%3A%2F%2Fwww.sec.gov%2Fthemes%2Fcustom%2Fuswds_sec%2Fassets%2Fimg%2Ffavicons%2Fapple-touch-icon.png&mode=avatar-48&exp=1793923200&sig=0ebee34ad85ed398 48w, /api/img-proxy?u=https%3A%2F%2Fwww.sec.gov%2Fthemes%2Fcustom%2Fuswds_sec%2Fassets%2Fimg%2Ffavicons%2Fapple-touch-icon.png&mode=avatar-96&exp=1793923200&sig=170272c57163b9ba 96w","changelogVersion","2026-10-01T08:00"]